Ciprofloxacin dosing

By: Klasens On: 01-Feb-2019
UpToDate

UpToDate

Cipro antibiotic also known as ciprofloxacin is a medication that kills various infections in pets. Since it has antibiotic properties it kills susceptible bacteria that cause different types of infections like respiratory infections, stomach infections or urinary tract infections. The medication is a prescription drug and should only be used according to the vet’s instructions. Ciprofloxacin contains a few active and inactive ingredients. The active ingredient is ciprofloxacin while the inactive ingredients include magnesium stearate, polyethylene glyco, titanium dioxide and crospovidone amidst others. The medication has fluoroquinolone properties that block bacterial DNA. This helps to kill susceptible bacteria within a short span of time. Ciprofloxacin ophthalmic solution is used to treat bacterial infections of the eye including conjunctivitis (pinkeye; infection of the membrane that covers the outside of the eyeball and the inside of the eyelid) and corneal ulcers (infection and loss of tissue in the clear front part of the eye). Ciprofloxacin ophthalmic ointment is used to treat conjunctivitis. Ciprofloxacin is in a class of antibiotics called fluoroquinolones. It works by killing the bacteria that cause infection. Ophthalmic ciprofloxacin comes as a solution (liquid) and an ointment to apply to the eyes. Ciprofloxacin ophthalmic solution is usually used often, between once every 15 minutes to once every 4 hours while awake for 7 to 14 days or longer. Ciprofloxacin ophthalmic ointment is usually applied 3 times a day for 2 days and then twice a day for 5 days.

DailyMed - CIPRO- <strong>ciprofloxacin</strong> hydrochloride tablet, film.

DailyMed - CIPRO- ciprofloxacin hydrochloride tablet, film.

UTI symptoms in women may include vaginal discharge, especially if the urethra is infected, or if an STD is involved. Ciprofloxacin and UTIs Many medical experts support using ciprofloxacin (Cipro) as an alternative and, in some cases, as the preferred first-line antibiotic for UTI treatment. However, others caution that widespread use of fluoroquinolones will promote increased resistance. FDA for complicated UTIs and pyelonephritis in children. Ciprofloxacin is an attractive alternative to TMP-SMX due to its high concentrations in the urogenital tissues, activity against the full range of uropathogens, and well-established clinical efficacy. Ciprofloxacin is useful in treating complicated and uncomplicated cystitis, recurrent UTI, and kidney infection. Ciprofloxacin dosage for UTI Adults: 250 mg every 12 hours for 7 to 14 days. Complicated infections require 500 mg every 12 hours. Children 1-17 years of age: 10–20 mg/kg (up to 750 mg) every 12 hours for 10–21 days. Cystitis (bladder infection) in women: The usual dosage is 250 mg every 12 hours for 3 days. As part of our continuous efforts to enhance Internet experience for our customers, we have upgraded our Domain Name System (DNS). This upgrading exercise will affect the DNS Internet Protocol (IP) address 202.188.0.133 where the IP address will be decommissioned in stages starting January 2018.

<i>Ciprofloxacin</i> 500mg Film-Coated Tablets - Summary of Product. - eMC

Ciprofloxacin 500mg Film-Coated Tablets - Summary of Product. - eMC

IV: 400 mg IV every 12 hours Oral: 500 mg orally every 12 hours Duration of therapy: 60 days Comments: -Therapy should be started as soon as possible after suspected/confirmed exposure. Use: For treatment of inhalational anthrax (postexposure) to reduce incidence/progression of disease after exposure to aerosolized Bacillus anthracis US CDC recommendations: -IV: 400 mg IV every 8 hours -Oral: 500 mg orally every 12 hours Duration of Therapy: Postexposure prophylaxis for B anthracis infection: 60 days Systemic anthrax: -With possible/confirmed meningitis: At least 2 to 3 weeks or until patient is clinically stable (whichever is longer) -When meningitis has been excluded: At least 2 weeks or until patient is clinically stable (whichever is longer) -Patients exposed to aerosolized spores will require prophylaxis to complete an antimicrobial regimen of 60 days from onset of illness. Cutaneous anthrax without systemic involvement: -Bioterrorism-related cases: 60 days -Naturally acquired cases: 7 to 10 days Comments: -The preferred drug for pregnant women -Recommended as a preferred oral drug for postexposure prophylaxis and for the treatment of cutaneous anthrax without systemic involvement -Recommended as the preferred IV drug for the treatment of systemic anthrax -Recommended for all strains (regardless of penicillin susceptibility or if susceptibility unknown) when used for postexposure prophylaxis, systemic anthrax when meningitis has been excluded, or cutaneous anthrax without systemic involvement -Recommended for use with a protein synthesis inhibitor when used for systemic anthrax; the addition of a bactericidal beta-lactam is recommended with possible/confirmed meningitis. -Systemic anthrax includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck. -Current guidelines should be consulted for additional information. IV: 400 mg IV every 12 hours Oral: 500 mg orally every 12 hours Duration of therapy: 60 days Comments: -Therapy should be started as soon as possible after suspected/confirmed exposure. Use: For treatment of inhalational anthrax (postexposure) to reduce incidence/progression of disease after exposure to aerosolized Bacillus anthracis US CDC recommendations: -IV: 400 mg IV every 8 hours -Oral: 500 mg orally every 12 hours Duration of Therapy: Postexposure prophylaxis for B anthracis infection: 60 days Systemic anthrax: -With possible/confirmed meningitis: At least 2 to 3 weeks or until patient is clinically stable (whichever is longer) -When meningitis has been excluded: At least 2 weeks or until patient is clinically stable (whichever is longer) -Patients exposed to aerosolized spores will require prophylaxis to complete an antimicrobial regimen of 60 days from onset of illness. Cutaneous anthrax without systemic involvement: -Bioterrorism-related cases: 60 days -Naturally acquired cases: 7 to 10 days Comments: -The preferred drug for pregnant women -Recommended as a preferred oral drug for postexposure prophylaxis and for the treatment of cutaneous anthrax without systemic involvement -Recommended as the preferred IV drug for the treatment of systemic anthrax -Recommended for all strains (regardless of penicillin susceptibility or if susceptibility unknown) when used for postexposure prophylaxis, systemic anthrax when meningitis has been excluded, or cutaneous anthrax without systemic involvement -Recommended for use with a protein synthesis inhibitor when used for systemic anthrax; the addition of a bactericidal beta-lactam is recommended with possible/confirmed meningitis. -Systemic anthrax includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck. Ciprofloxacin are indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy. The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight. Treatment of infections due to certain bacteria (e.g. Pseudomonas aeruginosa, Acinetobacter or Staphylococci) may require higher ciprofloxacin doses and co-administration with other appropriate antibacterial agents. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved. Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. If taken on an empty stomach, the active substance is absorbed more rapidly. Drug administration should begin as soon as possible after suspected or confirmed exposure. Ciprofloxacin tablets should not be taken with dairy products (e.g.

CIPRO - Food and Drug Administration
CIPRO - Food and Drug Administration

With oral administration, a 500 mg dose, given as 10 mL of the 5% CIPRO Suspension containing 250 mg ciprofloxacin/5mL is bioequivalent to the 500 mg tablet. A 10 mL volume of the 5% CIPRO Suspension containing 250 mg ciprofloxacin/5mL is bioequivalent to a 5 mL volume of the 10% CIPRO Suspension containing 500 mg ciprofloxacin/5mL. CIPRO prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects.

Ciprofloxacin dosing
Rating 4,2 stars - 944 reviews